Our Phase II early esophageal cancer (EC) detection study ESCEND started, coordinated by Vasilis Ntziachristos. The study follows exciting results showing up to 40% improvement in early EC using fluorescence molecular aging.
Our Phase II early esophageal cancer (EC) detection study ESCEND started, coordinated by Vasilis Ntziachristos. The study follows exciting results showing up to 40% improvement in early EC using fluorescence molecular aging.